BeStock  

Veracyte VCYT

US equityMarket cap rank #2674Diagnostics & Research
$25.13 +$0.09 (+0.36%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.18 +0.20%
Open$24.63
Prev close$25.04
Day range$24.53 – $25.60
Volume2.79M
Market cap$2.03B
P/E (TTM)16.3
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$151.75M+15.1% YoY
Operating profit$16.57M-27.8% YoY
Net profit$31.50M+64.6% YoY
Diluted EPS$0.38+58.3% YoY
Free cash flow$37.92M-9.6% YoY
Operating cash flow$40.26M

Revenue, last 8 quarters

$118.6MDec '24$114.5MMar '25$130.2MJun '25$131.9MSep '25$140.6MDec '25$139.1MMar '26$150.3MJun '26$151.8MSep '26

Net profit, last 8 quarters

$5.1MDec '24$7.0MMar '25$-980.0KJun '25$19.1MSep '25$41.1MDec '25$28.7MMar '26$25.5MJun '26$31.5MSep '26

Diluted EPS by quarter

0.06Dec '240.09Mar '25-0.01Jun '250.24Sep '250.51Dec '250.35Mar '260.31Jun '260.38Sep '26

Free cash flow by quarter

$20.4MDec '24$3.5MMar '25$32.3MJun '25$42.0MSep '25$48.8MDec '25$32.3MMar '26$43.0MJun '26$37.9MSep '26

Annual revenue

$117.5MFY20$219.5MFY21$296.5MFY22$361.1MFY23$445.8MFY24$517.1MFY25

Profitability & balance sheet

Gross margin72.0%
Operating margin17.1%
Net margin21.8%
Return on equity9.4%
Return on assets8.6%
Return on invested capital8.5%
Current ratio5.56
Liabilities / assets8.9%
Cash & investments$370.53M
Total debt$33.92M
Net cash (debt)$336.61M
Free cash flow / sales27.8%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $151.75M $150.32M $139.07M $517.15M $140.64M
Total Operating Revenue $151.75M $150.32M $139.07M $517.15M $140.64M
Cost of Revenue $44.65M $41.77M $37.91M $154.61M $38.66M
Gross Profit $107.10M $108.55M $101.16M $362.53M $101.97M
Operating Expense $90.54M $85.57M $78.51M $284.25M $64.78M
Selling and Admin Expenses $57.95M $55.71M $50.84M $210.95M $43.31M
-Selling & Marketing Expense $8.27M $8.69M $7.18M $30.96M $8.95M
-General & Admin Expense $49.69M $47.02M $43.65M $179.99M $34.36M
Research & Development $32.16M $29.44M $27.10M $70.81M $20.85M
Depreciation & Amortization & Depletion $422,000.00 $421,000.00 $579,000.00 $2.49M $622,000.00
-Depreciation & Amortization $422,000.00 $421,000.00 $579,000.00 $2.49M $622,000.00
Operating Profit $16.57M $22.98M $22.65M $78.28M $37.20M
Net Non-Operating Interest Income (Expense) $4.50M $3.88M $3.48M $12.72M $3.54M
Non-Operating Interest Income $4.50M $3.88M $3.48M $12.72M $3.54M
Non-Operating Interest Expense $0.00 $0.00 $0.00 $1,000.00 $0.00
Other Income (Expense) $50,000.00 -$341,000.00 $3.85M -$22.80M -$104,000.00
Gain on Sale of Security $35,000.00 -$341,000.00 $23,000.00 $3.97M -$89,000.00
Special Income (Charges) $0.00 $0.00 – -$27.21M $0.00
-Less:Write Off $0.00 $0.00 – $20.51M $0.00
-Gain on Sale Of Business $0.00 – – -$6.71M $0.00
Other Non-Operating Income (Expenses) $15,000.00 – $3.83M $436,000.00 -$15,000.00
Pretax Profit $21.12M $26.52M $29.97M $68.20M $40.63M
Tax -$10.38M $1.03M $1.27M $1.85M -$515,000.00
Net Profit $31.50M $25.49M $28.71M $66.35M $41.15M
Profit from Continuing Operations $31.50M $25.49M $28.71M $66.35M $41.15M
Net Income to Parent Company $31.50M $25.49M $28.71M $66.35M $41.15M
Net Income to Common Stockholders $31.50M $25.49M $28.71M $66.35M $41.15M
Basic EPS $0.39 $0.32 $0.36 $0.84 $0.52
Diluted EPS $0.38 $0.31 $0.35 $0.82 $0.51

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.57B $1.49B $1.44B $1.41B $1.41B
Total Current Assets $467.88M $574.78M $522.18M $488.38M $488.38M
Cash and Cash Equivalents & Short-Term Investments $370.53M $485.23M $439.06M $412.89M $412.89M
-Cash and Cash Equivalents $199.83M $299.52M $263.14M $362.58M $362.58M
-Short Term Investments $170.70M $185.71M $175.92M $50.31M $50.31M
Receivables $56.79M $54.18M $50.11M $44.66M $44.66M
-Accounts Receivable $56.79M $54.18M $50.11M $44.66M $44.66M
Inventory $25.82M $22.66M $21.42M $20.55M $20.55M
Other Current Assets $14.74M $12.71M $11.59M $10.28M $10.28M
Total Non-Current Assets $1.11B $911.59M $914.23M $917.64M $917.64M
Net PPE $59.97M $57.10M $58.52M $58.79M $58.79M
-Gross PPE $59.97M $57.10M $58.52M $102.27M $102.27M
Goodwill and Other Intangible Assets $1.04B $849.85M $853.02M $856.30M $856.30M
-Goodwill $855.58M $767.15M $767.15M $767.15M $767.15M
-Other Intangible Assets $184.88M $82.70M $85.86M $89.15M $89.15M
Other Non-Current Assets $4.95M $4.64M $2.69M $2.55M $2.55M
Total Liabilities $139.99M $97.96M $91.99M $96.44M $96.44M
Total Current Liabilities $84.21M $62.74M $56.12M $59.94M $59.94M
Payables $9.71M $8.02M $6.91M $4.59M $4.59M
-Accounts Payable $9.71M $8.02M $6.91M $4.59M $4.59M
Current Accrued Expenses $30.28M $22.55M $24.19M $21.34M $21.34M
Short-Term Debt and Capital Lease Obligation $6.81M $5.78M $4.35M $4.05M $4.05M
-Current Capital Lease Obligation $6.81M $5.78M $4.35M $4.05M $4.05M
Current Deferred Liabilities $864,000.00 $597,000.00 $749,000.00 $1.16M $1.16M
Other Current Liabilities $6.73M $662,000.00 $982,000.00 $1.33M $1.33M
Total Non-Current Liabilities $55.78M $35.23M $35.88M $36.51M $36.51M
Long Term Debt and Capital Lease Obligation $33.92M $34.33M $34.99M $35.60M $35.60M
-Long Term Capital Lease Obligation $33.92M $34.33M $34.99M $35.60M $35.60M
Non-Current Deferred Liabilities $1.62M $637,000.00 $636,000.00 $646,000.00 $646,000.00
Other Non-Current Liabilities $20.25M $259,000.00 $257,000.00 $257,000.00 $257,000.00
Total Equity $1.43B $1.39B $1.34B $1.31B $1.31B
Stockholders' Equity $1.43B $1.39B $1.34B $1.31B $1.31B
Capital Stock $81,000.00 $80,000.00 $80,000.00 $79,000.00 $79,000.00
-Common Stock $81,000.00 $80,000.00 $80,000.00 $79,000.00 $79,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.73B $1.72B $1.70B $1.70B $1.70B
Retained Earnings -$291.93M -$323.43M -$348.92M -$377.63M -$377.63M
Gains/Losses Not Affecting Retained Earnings -$8.06M -$7.94M -$8.22M -$8.21M -$8.21M
-Accumulated Depreciation – – – -$43.48M -$43.48M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $40.26M $45.83M $35.22M $136.31M $52.58M
Net cash flow from continuing operations $40.26M $45.83M $35.22M $136.31M $52.58M
Net Income from Continuing Operations $31.50M $25.49M $28.71M $66.35M $41.15M
Gain/Loss from Continuing Operations $46,000.00 $12,000.00 $286,000.00 $2.89M $2.86M
Depreciation & Depletion & Amortization $5.98M $4.84M $5.43M $21.42M $5.30M
Deferred Tax -$11.59M $1,000.00 -$10,000.00 -$581,000.00 -$568,000.00
Other Non-Cash Items $210,000.00 $386,000.00 $382,000.00 -$12.30M -$11.88M
Change in Working Capital $1.19M $1.74M -$11.73M -$2.30M $5.48M
-Change in Receivables -$2.23M -$4.16M -$5.57M -$708,000.00 $3.15M
-Change in Inventory -$1.33M -$1.24M -$870,000.00 -$2.86M -$219,000.00
-Change in Prepaid Assets -$1.68M -$1.12M -$1.31M -$2.05M $4.36M
-Change in Payables and Accrued Expense $6.71M $7.81M -$3.53M $5.28M -$1.21M
-Change in Other Current Assets -$320,000.00 -$319,000.00 -$132,000.00 $525,000.00 $194,000.00
-Change in Other Current Liabilities $43,000.00 $772,000.00 -$319,000.00 -$2.48M -$799,000.00
Net cash flow from investing -$139.47M -$13.55M -$127.96M -$9.21M -$5.43M
Net Cash Flow from Continuing Investing Activities -$139.47M -$13.55M -$127.96M -$9.21M -$5.43M
Net PPE Purchase and Sale -$2.33M -$2.86M -$2.96M -$9.68M -$3.78M
Net Investment Purchase and Sale $16.05M -$9.06M -$125.00M $3.31M $1.20M
Net Other Investing Changes $0.00 – – – –
Financing Cash Flow -$479,000.00 $4.14M -$6.63M -$4.22M -$149,000.00
Net Cash Flow from Continuing Financing Activities -$479,000.00 $4.14M -$6.63M -$4.22M -$149,000.00
Proceeds from Stock Option Exercised $3.33M $8.43M $2.74M $14.08M $3.51M
Net Other Financing Charges -$3.80M -$4.29M -$9.36M -$18.30M -$3.66M
Ending Cash Balance $201.47M $301.19M $264.79M $364.23M $364.23M
Net Change in Cash -$99.70M $36.42M -$99.38M $122.88M $47.00M
Beginning Cash Balance $301.19M $264.79M $364.23M $240.63M $317.21M
Effect of Exchange Rate Changes -$18,000.00 -$26,000.00 -$58,000.00 $719,000.00 $12,000.00
Free Cash Flow $37.92M $42.97M $32.25M $126.63M $48.80M
Net Business Purchase and Sale – – – -$2.85M -$2.85M

Discussion

No comments yet — be the first to weigh in on VCYT.

Sign in to join the discussion.

Scroll to Top